{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', '10.6.', 'Appendix 6: Liver Safety - Actions and Follow-up Assessments', 'Liver chemistry will be evaluated as specified in the SoA (Section 1.3) and Appendix 2', '(Section 10.2). Parameters will include ALT, AST, GGT, bilirubin, total bile acids, and ALP.', 'For subjects with ALT or AST > 1 X ULN and < 3 X ULN or total bilirubin or direct bilirubin', '> 1 X ULN and 1.5 X ULN, confirm the value within 24 to 48 hours. Contact the Medical', 'Monitor to determine the appropriate liver monitoring schedule (eg, weekly or twice a week).', 'The criteria requiring additional liver monitoring with possible interruption of study intervention', 'are detailed in Table 5.', 'Table 5:', 'Liver Chemistry Criteria Requiring Additional Monitoring with Possible', 'Interruption of Investigational Product', 'Criterion', 'Actions', 'ALT or AST > 3 X ULN and <5 X ULN', 'Notify the Medical Monitor within 24 hours of', 'or total bilirubin or direct bilirubin > 1.5', 'learning of the abnormality to discuss subject safety.', 'X ULN without symptoms believed to be', '\"Additional Liver Panel\" in Table 6 may be requested', 'related to liver injury or hypersensitivity,', 'by the Medical Monitor', 'and who can be monitored weekly for 4', 'Confirm values within 24 to 48 hours via repeat labs.', 'weeks', 'If unable to obtain repeat labs within 48 hours,', 'discontinue IP.', 'Decision to continue or interrupt study intervention', 'will be determined by the Investigator and the Medical', 'Monitor', 'Subject must return weekly or more frequently for', 'repeat liver chemistry tests (ALT, AST, GGT, ALP,', 'total bile acids, and bilirubin) until the abnormalities', 'resolve, stabilize, or return to baseline.', 'If at any time the subject meets liver chemistry', 'interruption criteria (as specified in Table 6), then', 'follow the instructions in \"Actions and Follow-up', 'Assessments\" in Table 6 and in consultation with the', 'Medical Monitor initiate relevant assessment', 'procedures.', 'In the case of AEs of interest (Section 10.3.3), potential re-challenge will be restricted to', 'potential DILI cases that have been assessed as unlikely or not related to IP by the HAC and after', 'liver enzymes have returned to baseline levels. When re-challenging with IP, obtain repeat liver', 'chemistries twice weekly in the first 2 weeks and then weekly for 6 weeks after the re-challenge.', 'If there is a rise in liver enzymes > 2 X ULN, the IP should be discontinued permanently.', 'The criteria requiring interruption of IP with additional liver monitoring is detailed in Table 6.', '65', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Table 6:', 'Liver Chemistry Criteria Requiring Investigational Product Interruption', 'and Additional Monitoring', 'Liver Chemistry - IP Interruption Criteria', 'ALT/AST (single occurrence)', 'ALT or AST 5 X ULN', 'ALT/AST', 'ALT or AST 3 X ULN persists for 4 weeks', '+ Bilirubin a,b', 'ALT or AST 3 X ULN and bilirubin > 2 X ULN (> 35% direct bilirubin)', '+ INR b', 'ALT or AST 3 X ULN and international normalized ratio (INR) > 1.5, if', 'INR measured', '+ Cannot Monitor', 'ALT or AST 3 X ULN and cannot be monitored weekly for 4 weeks', '+ Symptomatic', 'ALT or AST 3 X ULN associated with symptoms (new or worsening)', 'believed to be related to liver injury or hypersensitivity', 'Actions and Follow-up Assessments', 'Actions', 'Follow-Up Assessments', 'Immediately discontinue IP', 'Additional Liver Panel', 'Report the event to the Medical Monitor within', 'Viral hepatitis serology d', '24 hours', 'Obtain INR and recheck with each liver', 'Complete the liver event eCRF and complete an SAE', 'chemistry assessment until the ALT and/or AST', 'data collection tool if the event also met the criteria', 'values show downward trend', 'for an SAEb', 'Obtain blood sample for pharmacokinetic (PK)', 'Perform liver chemistry follow-up assessments.', 'analysis', 'Monitor the subject until liver chemistry test', 'Serum creatine phosphokinase (CPK)', 'abnormalities resolve, stabilize, or return to baseline', 'and lactate dehydrogenase (LDH)', '(see MONITORING)', 'Fractionate bilirubin, if total bilirubin', 'Do not restart/rechallenge subject with IP unless', '> 2 X ULN', 'Medical Monitor approval is granted', 'Obtain complete blood count with differential to', 'If restart/rechallenge not granted, permanently', 'assess eosinophilia', 'discontinue IP and continue subject in the study for', 'Record the appearance or worsening of clinical', 'any protocol specified follow up assessments', 'symptoms of liver injury, or hypersensitivity, on', 'the adverse event (AE) report form', 'MONITORING:', 'Record use of concomitant medications', '(including acetaminophen, herbal remedies, and', 'Repeat liver chemistry tests (include ALT, AST,', 'other over-the-counter medications) on the', 'GGT, alkaline phosphatase, total bile acids, bilirubin,', 'concomitant medications eCRF', 'and INR) and perform liver event follow-up', 'Record alcohol use on the liver event alcohol', 'assessments within 24 hours', 'intake eCRF', 'Monitor subject twice weekly until liver chemistry', 'Anti-nuclear antibody, anti-smooth muscle', 'test abnormalities resolve, stabilize, or return to', 'antibody, Type 1 anti-liver kidney microsomal', 'baseline', 'antibodies, and quantitative total', 'A specialist or hepatology consultation is', 'immunoglobulin G (IgG) or gamma globulins', 'recommended', 'Serum acetaminophen assay', 'Liver imaging (ultrasound, magnetic resonance,', 'or computerized tomography) and/or liver', 'biopsy to evaluate liver disease', 'a.', 'Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not', 'immediately available, discontinue IP if ALT or AST > 3 X ULN and bilirubin > 2 X ULN. Additionally, if', 'serum bilirubin fractionation testing is unavailable, record the absence/presence of detectable urinary', 'bilirubin on dipstick which is indicative of direct bilirubin elevations suggesting liver injury.', '66', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}